Afghanistan vs Sri Lanka: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Afghanistan
0.3%
in 2024
Sri Lanka
0.3%
in 2024
Afghanistan rank
85th
Sri Lanka rank
85th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Afghanistan
- Sri Lanka
How they compare
Afghanistan currently reports 0.3% against 0.3% in Sri Lanka, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Afghanistan ahead.
Afghanistan ranks 85th and Sri Lanka ranks 85th of 246 countries.
Afghanistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | Afghanistan |
| 2020s | 0.3% | 0.3% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Afghanistan or Sri Lanka?
- Afghanistan, at 0.3% against 0.3% in Sri Lanka as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Afghanistan and Sri Lanka?
- 0.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Sri Lanka?
- 10 years are reported by both, from 2015 to 2024.
- How do Afghanistan and Sri Lanka rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Afghanistan ranks 85th and Sri Lanka ranks 85th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.